ALK-abello (AKBLF) Price & Analysis

Compare

11 Followers

AKBLF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$18.45 - $28.00

Previous CloseN/A

Volume1.00

Average Volume (3M)69.00

Market Cap

$5.91B

Enterprise Value$38.08B

Total Cash (Recent Filing)$517.00M

Total Debt (Recent Filing)kr800.00M

Price to Earnings (P/E)43.0

Beta0.80

Next Earnings

Aug 21, 2025

EPS Estimate

0.2

Last Dividend Ex-Date

Mar 16, 2017

Dividend YieldN/A

Share Statistics

EPS (TTM)0.24

Shares Outstanding202,567,200

10 Day Avg. Volume0

30 Day Avg. Volume69

Financial Highlights & Ratios

PEG Ratio3.03

Price to Book (P/B)6.62

Price to Sales (P/S)0.00

P/FCF Ratio2.10K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$28.17

Price Target Upside7.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering0

ALK-abello News

PremiumThe Fly

ARS Pharmaceuticals Air Lease ALK-Abello

25d ago

SPRY

PremiumCompany Announcements

ALK-abello A/S Earnings Call Highlights Robust Growth

15d ago

PremiumCompany Announcements

ALK-Abelló A/S Reports Strong Q1 2025 Growth

21d ago

PremiumPre-Earnings

ALK-abello A/S Class B (AKBLF) Q1 Earnings Cheat Sheet

24d ago

PremiumThe Fly

ALK-Abello says FDA approves label expansion for Odactra

3M ago

PremiumCompany Announcements

ALK-abello A/S: Record Growth and Market Challenges

3M ago

PremiumCompany Announcements

ALK-Abelló Reports Record Growth and Strong Outlook

3M ago

PremiumPre-Earnings

AKBLF Upcoming Earnings Report: What to Expect?

3M ago

See All AKBLF News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

0.03% Insiders

3.54% Mutual Funds

― Other Institutional Investors

92.19% Public Companies and

Individual Investors

Detailed Ownership Overview >

AKBLF FAQ

What was ALK-abello A/S Class B’s price range in the past 12 months?

ALK-abello A/S Class B lowest stock price was $18.45 and its highest was $28.00 in the past 12 months.

What is ALK-abello A/S Class B’s market cap?

ALK-abello A/S Class B’s market cap is $5.91B.

When is ALK-abello A/S Class B’s upcoming earnings report date?

ALK-abello A/S Class B’s upcoming earnings report date is Aug 21, 2025 which is in 86 days.

How were ALK-abello A/S Class B’s earnings last quarter?

ALK-abello A/S Class B released its earnings results on May 06, 2025. The company reported $0.244 earnings per share for the quarter, beating the consensus estimate of $0.206 by $0.038.

Is ALK-abello A/S Class B overvalued?

According to Wall Street analysts ALK-abello A/S Class B’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ALK-abello A/S Class B pay dividends?

ALK-abello A/S Class B pays a Notavailable dividend of $0.038 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here

What is ALK-abello A/S Class B’s EPS estimate?

ALK-abello A/S Class B’s EPS estimate is 0.2.

How many shares outstanding does ALK-abello A/S Class B have?

ALK-abello A/S Class B has 202,567,200 shares outstanding.

What happened to ALK-abello A/S Class B’s price movement after its last earnings report?

ALK-abello A/S Class B reported an EPS of $0.244 in its last earnings report, beating expectations of $0.206. Following the earnings report the stock price went up 5.329%.

Which hedge fund is a major shareholder of ALK-abello A/S Class B?

Currently, no hedge funds are holding shares in AKBLF

Company Description

ALK-abello A/S Class B

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

AKBLF Company Deck

AKBLF Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a positive outlook for ALK, highlighting strong revenue and earnings growth, supported by successful tablet sales and strategic advancements in the pediatric segment. Despite challenges in China, the company maintains its full-year outlook with confidence.Read More>

AKBLF Stock 12 Month Forecast

Average Price Target

$28.17

▲( 7.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","14":"$14","19":"$19","24":"$24","29":"$29"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.17106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.17106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,14,19,24,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2021","6":"Nov<br/>2022","9":"Jun<br/>2023","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.12,22.585466153846156,23.05093230769231,23.51639846153846,23.981864615384616,24.44733076923077,24.912796923076925,25.378263076923076,25.84372923076923,26.309195384615386,26.77466153846154,27.240127692307695,27.705593846153846,{"y":28.17106,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.12,22.585384615384616,23.05076923076923,23.51615384615385,23.981538461538463,24.446923076923078,24.912307692307692,25.37769230769231,25.843076923076925,26.30846153846154,26.773846153846154,27.239230769230772,27.704615384615387,{"y":28.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.12,22.585466153846156,23.05093230769231,23.51639846153846,23.981864615384616,24.44733076923077,24.912796923076925,25.378263076923076,25.84372923076923,26.309195384615386,26.77466153846154,27.240127692307695,27.705593846153846,{"y":28.17106,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.35,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.65,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.92,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.82,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.32,"date":1640995200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.32,"date":1640995200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.42,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.76,"date":1682899200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.87,"date":1685577600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >